大和发表研究报告指，中国生物制药(01177.HK) 去年受到创新药带动，收入按年增长10.2%；毛利率按年升0.5个百分点；销售及行政支出比率保持稳定于42.1%；研究开发比率升0.8个百分点；经调整净利润增33.5%。
该行将中生制药下个财政年度的收入预测上调9%至12%，重申其“买入”评级，目标价由3.5元上调至4元。该行又将集团今明两年的创新药收入预测上调4%和15%，分别至150亿和190亿元人民币。不过，该行下调集团今年的每股盈测8%，以主要反映非核心收入下降。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-14 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.